Eisai Plans Transfer of North Carolina Mfg Facility to Biogen
Eisai Co., Ltd.’s US subsidiary Eisai Inc. has agreed to transfer ownership of its manufacturing facility in Research Triangle Park in North Carolin to Biogen.
The agreement expands upon the strategic manufacturing alliance agreement concerning the North Carolina plant entered into in December 2012. Under the new agreement, Eisai will transfer to Biogen the entire North Carolina plant site, including the oral solid dose (OSD) facility that had been leased by Biogen. Additionally, Biogen will continue to manufacture OSD products for Eisai, and Eisai will subsequently commission Biogen to manufacture all Eisai parenteral products currently made at the parenteral facility. In accordance with the execution of this agreement, approximately 100 Eisai Inc. employees may be offered employment at Biogen, effective upon closing of the deal. This agreement is expected to close in the second quarter, subject to the satisfaction of all customary provisions generally attached to similar transactions.
This decision is based on Eisai’s global logistics strategy which aims to optimize the global supply chain. After the transfer of manufacturing operations to Biogen takes place, Eisai will continue to base supply chain management services in the Research Triangle Park area. Together with maintaining operations of global contract manufacturing management and quality assurance in North Carolina, production at the Baltimore plant in Maryland will continue unchanged to supply products for the United States as well as the global market.